About six months after rolling out voice AI in its call centers, Allina Health is already seeing signs that the tool is doing a good job of improving the patient experience. The technology is reducing patients’ average call times by 5-10 seconds, and 80% of calls are now answered in 45 seconds or less. The…
Smaller healthcare providers need support rather than being threatened with penalties, cybersecurity expert says
Saniona’s drug candidate could expand Jazz Pharmaceuticals portfolio in epilepsy. But this preclinical small molecule will need to show advantages in safety and efficacy to compete with Biohaven Pharmaceuticals and Xenon Pharmaceuticals, each with clinical-stage drugs that hit the same epilepsy target. The post Jazz Pharma Broadens Its Prospects in Epilepsy With Deal for Selective…
By KIM BELLARD Perhaps you are the kind of person who acts as though that the food in the grocery store somehow magically appears, with no supply chain vulnerabilities along the way. You trust that the water that you drink and the air you breathe are just fine, with no worries about what might have…
Chuanzi Yue and Marisa Miraldo argue in a recent Health Affairs Forefront piece that the answer is ‘yes’, but I am highly skeptical of their claim. Will IRA cause firms to allocate funds from marketing to R&D? One point they make is that the IRA’s Medicare Drug Price Negotiation program will reduce pharmaceutical expenses on…
Triumphant music plays as cancer patients go camping, do some gardening, and watch fireworks in ads for Opdivo+Yervoy, a combination of immunotherapies to treat metastatic melanoma and lung cancer. Ads for Skyrizi, a medicine to treat plaque psoriasis and other illnesses, show patients snorkeling and riding bikes — flashing their rash-free elbows. People with Type…
In 1942, a young Black man named Cleo Wright was removed from a Sikeston, Missouri, jail and lynched by a white mob. Nearly 80 years later, another young Black man, Denzel Taylor, was shot at least 18 times by police in the same small community. In the hourlong “Silence in Sikeston” documentary film broadcast on…
Editas Medicine says its in vivo gene-editing therapy for hemoglobinopathies has best-in-class potential, but the company plans to out-license or partner that program. Editas is shifting focusing to in vivo gene-editing therapies. The post Editas Medicine Seeks Partner for Ex Vivo Gene-Editing Program as Focus Turns to In Vivo R&D appeared first on MedCity News.
As part of the 2024 KFF Women’s Health Survey, a nationally representative sample of 1,191 men ages 18 to 64 were surveyed on a broad range of health issues. This data note highlights their responses to their experiences, knowledge, and perspectives about vasectomy services.